These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31541547)

  • 1. Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.
    Chesnokov A; Patel MC; Mishin VP; De La Cruz JA; Lollis L; Nguyen HT; Dugan V; Wentworth DE; Gubareva LV
    J Infect Dis; 2020 Jan; 221(3):367-371. PubMed ID: 31541547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
    Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
    J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Chon I; Wagatsuma K; Saito R; Tang JW; Isamu S; Suzuki E; Shirahige Y; Kawashima T; Minato M; Kodo N; Masaki H; Hamabata H; Yoshioka S; Ichikawa Y; Sun Y; Li J; Otoguto T; Watanabe H
    Antiviral Res; 2024 Sep; 229():105956. PubMed ID: 38969237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
    Jones JC; Pascua PNQ; Fabrizio TP; Marathe BM; Seiler P; Barman S; Webby RJ; Webster RG; Govorkova EA
    Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8593-8601. PubMed ID: 32217734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
    Takashita E; Kawakami C; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T;
    Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
    Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
    mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
    Taniguchi K; Noshi T; Omoto S; Sato A; Shishido T; Matsuno K; Okamatsu M; Krauss S; Webby RJ; Sakoda Y; Kida H
    Arch Virol; 2024 Jan; 169(2):29. PubMed ID: 38216710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High throughput profiling identified PA-L106R amino acid substitution in A(H1N1)pdm09 influenza virus that confers reduced susceptibility to baloxavir in vitro.
    Chen D; Su W; Choy KT; Chu YS; Lin CH; Yen HL
    Antiviral Res; 2024 Sep; 229():105961. PubMed ID: 39002800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
    Gubareva LV; Mishin VP; Patel MC; Chesnokov A; Nguyen HT; De La Cruz J; Spencer S; Campbell AP; Sinner M; Reid H; Garten R; Katz JM; Fry AM; Barnes J; Wentworth DE
    Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
    Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
    Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
    Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
    PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.
    Hickerson BT; Adams SE; Barman S; Miller L; Lugovtsev VY; Webby RJ; Ince WL; Donnelly RP; Ilyushina NA
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0000922. PubMed ID: 35262375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
    Jones JC; Rovito SW; Penaflor MK; Webby RJ; Govorkova EA
    Antiviral Res; 2022 Aug; 204():105369. PubMed ID: 35738347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.
    Hickerson BT; Petrovskaya SN; Dickensheets H; Donnelly RP; Ince WL; Ilyushina NA
    J Virol; 2023 Jul; 97(7):e0015423. PubMed ID: 37404185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets.
    Imai M; Yamashita M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Kiso M; Murakami J; Yasuhara A; Takada K; Ito M; Nakajima N; Takahashi K; Lopes TJS; Dutta J; Khan Z; Kriti D; van Bakel H; Tokita A; Hagiwara H; Izumida N; Kuroki H; Nishino T; Wada N; Koga M; Adachi E; Jubishi D; Hasegawa H; Kawaoka Y
    Nat Microbiol; 2020 Jan; 5(1):27-33. PubMed ID: 31768027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
    Uehara T; Hayden FG; Kawaguchi K; Omoto S; Hurt AC; De Jong MD; Hirotsu N; Sugaya N; Lee N; Baba K; Shishido T; Tsuchiya K; Portsmouth S; Kida H
    J Infect Dis; 2020 Jan; 221(3):346-355. PubMed ID: 31309975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.
    Lee LY; Zhou J; Koszalka P; Frise R; Farrukee R; Baba K; Miah S; Shishido T; Galiano M; Hashimoto T; Omoto S; Uehara T; Mifsud EJ; Collinson N; Kuhlbusch K; Clinch B; Wildum S; Barclay WS; Hurt AC
    PLoS Pathog; 2021 May; 17(5):e1009527. PubMed ID: 33956888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.
    Mhamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
    J Gen Virol; 2021 Oct; 102(10):. PubMed ID: 34661516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
    Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
    Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
    Osada H; Chon I; Phyu WW; Wagatsuma K; Nagata N; Kawashima T; Sato I; Saito T; Kodo N; Masaki H; Asoh N; Tsuchihashi Y; Shirahige Y; Ono Y; Shimada Y; Hamabata H; Saito K; Saito R
    Antiviral Res; 2021 Apr; 188():105036. PubMed ID: 33577807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.